Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Stopped Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator

Conditions

• Transcatheter Aortic Valve Replacement

Interventions

• DRUG: Rivaroxaban (Xarelto, BAY59-7939)
• DRUG: Acetylsalicylic Acid (ASA)
• DRUG: Clopidogrel
• DRUG: Rivaroxaban (Xarelto, BAY59-7939)
• DRUG: Vitamin K antagonist (VKA)

Sponsor

Bayer

Collaborators

• [object Object]